A Canadian research team found low doses of the blood thinner rivaroxaban, marketed as Xarelto from Johnson & Johnson unit Janssen Pharmaceuticals, reduced the risk of blood clot recurrence by about 70% compared with aspirin, without increasing the risk of bleeding.